Pharmacogenetic meta-analysis of baseline risk factors, pharmacodynamic, efficacy and tolerability endpoints from two large global cardiovascular outcomes trials for darapladib

Darapladib, a lipoprotein-associated phospholipase A2 (Lp-PLA(2)) inhibitor, failed to demonstrate efficacy for the primary endpoints in two large phase III cardiovascular outcomes trials, one in stable coronary heart disease patients (STABILITY) and one in acute coronary syndrome (SOLID-TIMI 52). N...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:PLoS One
Hlavní autoři: Yeo, Astrid, Li, Li, Warren, Liling, Aponte, Jennifer, Fraser, Dana, King, Karen, Johansson, Kelley, Barnes, Allison, MacPhee, Colin, Davies, Richard, Chissoe, Stephanie, Tarka, Elizabeth, O’Donoghue, Michelle L., White, Harvey D., Wallentin, Lars, Waterworth, Dawn
Médium: Artigo
Jazyk:Inglês
Vydáno: Public Library of Science 2017
Témata:
Research Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5533343/
https://ncbi.nlm.nih.gov/pubmed/28753643
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0182115
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky